minoxidil
Phase 3Completed 0 views this week 0 watching⚡ Active
Interest: 40/100
40
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Androgenetic Alopecia
Conditions
Androgenetic Alopecia
Trial Timeline
Oct 1, 2003 → Jul 1, 2004
NCT ID
NCT00151515About minoxidil
minoxidil is a phase 3 stage product being developed by Johnson & Johnson for Androgenetic Alopecia. The current trial status is completed. This product is registered under clinical trial identifier NCT00151515. Target conditions include Androgenetic Alopecia.
What happened to similar drugs?
0 of 6 similar drugs in Androgenetic Alopecia were approved
Approved (0) Terminated (0) Active (6)
Hype Score Breakdown
Clinical
17
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00151515 | Phase 3 | Completed |
Competing Products
12 competing products in Androgenetic Alopecia
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Minoxidil + vehicle of 5% Minoxidil topical foam | Johnson & Johnson | Phase 2 | 35 |
| 5% Minoxidil Topical Foam + Vehicle Topical Foam | Johnson & Johnson | Phase 3 | 40 |
| Cyproterone Acetate (Androcur, BAY94-8367) | Bayer | Pre-clinical | 23 |
| Clascoterone 5% solution + Vehicle solution | ICON plc. | Phase 3 | 37 |
| Clascoterone 5% solution + Vehicle solution | ICON plc. | Phase 3 | 41 |
| VDPHL01 | Veradermics | Phase 2 | 33 |
| VDPHL01 QD + Placebo + VDPHL01 BID + Placebo | Veradermics | Phase 3 | 41 |
| VDPHL01 + Placebo | Veradermics | Phase 2/3 | 36 |
| VDPHL01 + Placebo | Veradermics | Phase 3 | 38 |
| MK0906, finasteride / Duration of Treatment : 48 Weeks + Comparator : placebo (unspecified) / Duration of Treatment : 48 Weeks | Organon | Phase 3 | 34 |
| ABS-201 IV Single Dose + Placebo IV + ABS-201 SC Multiple Doses + Placebo SC Injection | AbSci | Phase 1/2 | 29 |
| ATI-50002 | Aclaris Therapeutics | Phase 2 | 25 |